Search research articles
Contact Us
Filters
Showing results (51-60 of 72) with videos related to
Page
of 8
Sort By:
Molecular Cancer Therapeutics
|
June 20, 2017
Optimization of <i>RAS/BRAF</i> Mutational Analysis Confirms Improvement in Patient Selection for Clinical Benefit to Anti-EGFR Treatment in Metastatic Colorectal Cancer
Cristina Santos, Daniel Azuara, Rocio Garcia-Carbonero, et al.
Genome Research
|
February 10, 2017
Genome-wide chemical mutagenesis screens allow unbiased saturation of the cancer genome and identification of drug resistance mutations
Jonathan S Brammeld, Mia Petljak, Inigo Martincorena, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 28, 2015
Emergence of Multiple EGFR Extracellular Mutations during Cetuximab Treatment in Colorectal Cancer
Sabrina Arena, Beatriz Bellosillo, Giulia Siravegna, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 8, 2022
Liquid Biopsy Detects Early Molecular Response and Predicts Benefit to First-Line Chemotherapy plus Cetuximab in Metastatic Colorectal Cancer: PLATFORM-B Study
Joana Vidal, Maria Concepción Fernández-Rodríguez, David Casadevall, et al.
Plos One
|
September 30, 2016
Multi-Center Evaluation of the Fully Automated PCR-Based Idylla™ KRAS Mutation Assay for Rapid KRAS Mutation Status Determination on Formalin-Fixed Paraffin-Embedded Tissue of Human Colorectal Cancer
Jérôme Solassol, Julie Vendrell, Bruno Märkl, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 1, 2026
Next generation sequencing of circulating tumor DNA for precision medicine in patients with advanced biliary tract cancers
Laura Visa, Jordi Badia-Ramentol, Maria Concepción Fernández, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 16, 2013
Level of HER2 gene amplification predicts response and overall survival in HER2-positive advanced gastric cancer treated with trastuzumab
Carlos Gomez-Martin, Jose Carlos Plaza, Roberto Pazo-Cid, et al.
Nature Communications
|
December 2, 2021
Intermittent BRAF inhibition in advanced BRAF mutated melanoma results of a phase II randomized trial
Maria Gonzalez-Cao, Clara Mayo de Las Casas, Juana Oramas, et al.
Gut
|
April 14, 2026
Stromal biomarker-based framework for identifying pMMR/MSS and dMMR/MSI colorectal cancers with poor outcomes and limited benefit from immunotherapy
Mar Iglesias Coma, Jordi Badia-Ramentol, Carolina Martinez-Ciarpaglini, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie
|
June 8, 2024
Changes In Serum CXCL13 Levels Are Associated With Outcomes of Colorectal Cancer Patients Undergoing First-Line Oxaliplatin-Based Treatment
Sara Cabrero-de Las Heras, Xavier Hernández-Yagüe, Andrea González, et al.
Page
of 8
Search research articles
Search
Showing results (51-60 of 72) with videos related to
Sort By:
Page
of 8
Molecular Cancer Therapeutics
|
June 20, 2017
Optimization of <i>RAS/BRAF</i> Mutational Analysis Confirms Improvement in Patient Selection for Clinical Benefit to Anti-EGFR Treatment in Metastatic Colorectal Cancer
Cristina Santos, Daniel Azuara, Rocio Garcia-Carbonero, et al.
Genome Research
|
February 10, 2017
Genome-wide chemical mutagenesis screens allow unbiased saturation of the cancer genome and identification of drug resistance mutations
Jonathan S Brammeld, Mia Petljak, Inigo Martincorena, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 28, 2015
Emergence of Multiple EGFR Extracellular Mutations during Cetuximab Treatment in Colorectal Cancer
Sabrina Arena, Beatriz Bellosillo, Giulia Siravegna, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 8, 2022
Liquid Biopsy Detects Early Molecular Response and Predicts Benefit to First-Line Chemotherapy plus Cetuximab in Metastatic Colorectal Cancer: PLATFORM-B Study
Joana Vidal, Maria Concepción Fernández-Rodríguez, David Casadevall, et al.
Plos One
|
September 30, 2016
Multi-Center Evaluation of the Fully Automated PCR-Based Idylla™ KRAS Mutation Assay for Rapid KRAS Mutation Status Determination on Formalin-Fixed Paraffin-Embedded Tissue of Human Colorectal Cancer
Jérôme Solassol, Julie Vendrell, Bruno Märkl, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 1, 2026
Next generation sequencing of circulating tumor DNA for precision medicine in patients with advanced biliary tract cancers
Laura Visa, Jordi Badia-Ramentol, Maria Concepción Fernández, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 16, 2013
Level of HER2 gene amplification predicts response and overall survival in HER2-positive advanced gastric cancer treated with trastuzumab
Carlos Gomez-Martin, Jose Carlos Plaza, Roberto Pazo-Cid, et al.
Nature Communications
|
December 2, 2021
Intermittent BRAF inhibition in advanced BRAF mutated melanoma results of a phase II randomized trial
Maria Gonzalez-Cao, Clara Mayo de Las Casas, Juana Oramas, et al.
Gut
|
April 14, 2026
Stromal biomarker-based framework for identifying pMMR/MSS and dMMR/MSI colorectal cancers with poor outcomes and limited benefit from immunotherapy
Mar Iglesias Coma, Jordi Badia-Ramentol, Carolina Martinez-Ciarpaglini, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie
|
June 8, 2024
Changes In Serum CXCL13 Levels Are Associated With Outcomes of Colorectal Cancer Patients Undergoing First-Line Oxaliplatin-Based Treatment
Sara Cabrero-de Las Heras, Xavier Hernández-Yagüe, Andrea González, et al.
Page
of 8